Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT05122546 trial: what clinicians have said so far
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
- NCT05122546 ↗
- Active, not recruiting
- City of Hope Medical Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05122546 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05122546 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma; Advanced Papillary Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Clear Cell Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
- Interventions
- Cabozantinib S-malate; Clostridium butyricum CBM 588 Probiotic Strain; Nivolumab
- Arms
- Arm 2 (CBM588, nivolumab, cabozantinib S-malate) · Experimental
- Arm I (nivolumab, cabozantinib S-malate) · Active comparator
- Enrollment
- 31
- Primary outcomes
- Change in Bifidobacterium composition of stool
- Sponsor
- City of Hope Medical Center with National Cancer Institute (NCI)
- Start
- Nov 1, 2021
- Primary completion
- Jan 12, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05122546 · updated Mar 5, 2026
Publications
linked from the registry- Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, Frankel P, Llamas-Quitiquit M, Hsu J, Zengin ZB, Alcantara M, Castro D, Mercier B, Chawla N, Chehrazi-Raffle A, Barragan-Carrillo R, Jaime-Casas S, Govindarajan A, Gillece J, Trent J, Lee PP, Parks TP, Takahashi M, Hayashi A, Kortylewski M, Caporaso JG, Lee K, Tripathi A, Pal SK. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2024 Sep;30(9):2576-2585. doi: 10.1038/s41591-024-03086-4. Epub 2024 Jun 28. PubMed 38942995